UBS Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.3M | Sell |
138,388
-101,700
| -42% | -$14.2M | ﹤0.01% | 2638 |
|
|
2025
Q4 | $29.5M | Sell |
240,088
-72,900
| -23% | -$8.86M | ﹤0.01% | 2195 |
|
|
2025
Q3 | $34.7M | Buy |
312,988
+24,800
| +9% | +$2.82M | 0.01% | 1996 |
|
|
2025
Q2 | $32M | Sell |
288,188
-252,242
| -47% | -$26.8M | 0.01% | 1916 |
|
|
2025
Q1 | $60.6M | Sell |
540,430
-99,858
| -16% | -$10.3M | 0.01% | 1312 |
|
|
2024
Q4 | $59.1M | Buy |
640,288
+130,000
| +25% | +$11.7M | 0.01% | 1316 |
|
|
2024
Q3 | $42.8M | Buy |
510,288
+102,000
| +25% | +$7.78M | 0.01% | 1259 |
|
|
2024
Q2 | $28M | Buy |
408,288
+57,088
| +16% | +$3.81M | 0.01% | 1421 |
|
|
2024
Q1 | $25.7M | Sell |
351,200
-240,700
| -41% | -$18.5M | 0.01% | 1496 |
|
|
2023
Q4 | $47.9M | Sell |
591,900
-27,800
| -4% | -$2.16M | 0.01% | 987 |
|
|
2023
Q3 | $46.4M | Buy |
619,700
+70,400
| +13% | +$5.41M | 0.02% | 906 |
|
|
2023
Q2 | $42.3M | Sell |
549,300
-216,400
| -28% | -$17.3M | 0.01% | 925 |
|
|
2023
Q1 | $63.5M | Buy |
765,700
+50,900
| +7% | +$4.22M | 0.02% | 663 |
|
|
2022
Q4 | $61.4M | Buy |
714,800
+344,900
| +93% | +$27.3M | 0.02% | 704 |
|
|
2022
Q3 | $22.8M | Buy |
369,900
+109,000
| +42% | +$6.87M | 0.01% | 1182 |
|
|
2022
Q2 | $16.1M | Sell |
260,900
-339,400
| -57% | -$21M | 0.01% | 1468 |
|
|
2022
Q1 | $35.7M | Sell |
600,300
-248,300
| -29% | -$15.9M | 0.01% | 1049 |
|
|
2021
Q4 | $61.6M | Buy |
848,600
+3,081
| +0.4% | +$212K | 0.02% | 840 |
|
|
2021
Q3 | $59.1M | Buy |
845,519
+391,606
| +86% | +$27.5M | 0.02% | 784 |
|
|
2021
Q2 | $31.3M | Sell |
453,913
-68,439
| -13% | -$4.57M | 0.01% | 1135 |
|
|
2021
Q1 | $33.8M | Buy |
522,352
+24,852
| +5% | +$1.6M | 0.01% | 1083 |
|
|
2020
Q4 | $29M | Buy |
497,500
+28,640
| +6% | +$1.73M | 0.01% | 1108 |
|
|
2020
Q3 | $29.6M | Buy |
468,860
+11,500
| +3% | +$797K | 0.01% | 935 |
|
|
2020
Q2 | $35.2M | Sell |
457,360
-89,012
| -16% | -$6.82M | 0.01% | 771 |
|
|
2020
Q1 | $40.8M | Buy |
546,372
+145,172
| +36% | +$10M | 0.02% | 635 |
|
|
2019
Q4 | $26.1M | Buy |
401,200
+160,900
| +67% | +$10.5M | 0.01% | 1182 |
|
|
2019
Q3 | $15.2M | Buy |
240,300
+46,800
| +24% | +$3.06M | 0.01% | 1435 |
|
|
2019
Q2 | $13.1M | Sell |
193,500
-50,720
| -21% | -$3.34M | 0.01% | 1549 |
|
|
2019
Q1 | $15.9M | Sell |
244,220
-359,380
| -60% | -$23.9M | 0.01% | 1305 |
|
|
2018
Q4 | $37.8M | Buy |
603,600
+113,900
| +23% | +$7.96M | 0.02% | 738 |
|
|
2018
Q3 | $37.8M | Sell |
489,700
-129,984
| -21% | -$9.82M | 0.02% | 820 |
|
|
2018
Q2 | $43.9M | Sell |
619,684
-5,021,568
| -89% | -$355M | 0.02% | 711 |
|
|
2018
Q1 | $425M | Buy |
5,641,252
+5,370,827
| +1,986% | +$427M | 0.18% | 126 |
|
|
2017
Q4 | $19.4M | Buy |
270,425
+128,266
| +90% | +$9.74M | 0.01% | 1221 |
|
|
2017
Q3 | $11.5M | Sell |
142,159
-938,065
| -87% | -$71.7M | 0.01% | 1499 |
|
|
2017
Q2 | $76.5M | Buy |
1,080,224
+546,108
| +102% | +$36.3M | 0.04% | 422 |
|
|
2017
Q1 | $36.3M | Buy |
534,116
+290,187
| +119% | +$20.4M | 0.02% | 690 |
|
|
2016
Q4 | $17.5M | Buy |
243,929
+213,068
| +690% | +$15.8M | 0.01% | 1118 |
|
|
2016
Q3 | $2.44M | Sell |
30,861
-45,775
| -60% | -$3.72M | ﹤0.01% | 2663 |
|
|
2016
Q2 | $6.39M | Buy |
76,636
+47,946
| +167% | +$4.26M | ﹤0.01% | 1744 |
|
|
2016
Q1 | $2.63M | Sell |
28,690
-390,730
| -93% | -$35.2M | ﹤0.01% | 2423 |
|
|
2015
Q4 | $42.4M | Buy |
419,420
+74,409
| +22% | +$7.74M | 0.03% | 562 |
|
|
2015
Q3 | $33.9M | Sell |
345,011
-68,449
| -17% | -$7.6M | 0.02% | 625 |
|
|
2015
Q2 | $48.4M | Sell |
413,460
-373,473
| -47% | -$40.8M | 0.03% | 534 |
|
|
2015
Q1 | $77.2M | Buy |
786,933
+67,776
| +9% | +$6.88M | 0.05% | 376 |
|
|
2014
Q4 | $67.8M | Buy |
+719,157
| New | +$74.4M | 0.05% | 417 |
|
Other funds holding GILD
VCM
VPM
UBS Group's GILD Position: Q1 2026 in Review
UBS Group reduced its Gilead Sciences (GILD) stake by 18% in Q1 2026, selling an estimated $119M and leaving 3,930,216 shares worth $548M. The position accounts for 0.08% of the portfolio, ranked #248.
UBS Group first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. The position peaked at $744M in Q2 2015. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- UBS Group held 3,930,216 shares of Gilead Sciences worth $548M as of Q1 2026.
- UBS Group sold 849,463 Gilead Sciences shares in Q1 2026, an estimated $119M.
- Gilead Sciences made up 0.08% of UBS Group's portfolio in Q1 2026, its #248 holding.
- UBS Group first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Gilead Sciences position peaked at $744M in Q2 2015.
- 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.